Search

Introduction: Our group has developed a paracorporeal artificial lung (PAL) attached in a pulmonary artery (PA) to PA in series configuration to address profound respiratory failure and serve as a bridge to transplant and/or recovery. We recently designed, developed and converted our passive pre-PAL compliance chamber to an active, synchronized, counterpulsating assist device to relieve right heart strain and offset increased work placed on the right ventricle when the PAL is attached. In this study, we evaluated the safety and performance of both a valved and nonvalved optional active compliance chamber (OACC) in a PA-PA PAL for right heart assistance in normal adult sheep. Methods: Eleven sheep (30-50 kg) were divided into nonvalved OACC (n=6) and valved (n=5) OACC groups. To mimic pulmonary hypertension, a C-clamp was placed distal to the OACC-PAL and occluded until a 20% decrease in cardiac output (CO) was achieved. The OACC was activated, and right ventricular pressure (RVP), pulmonary artery pressure (PAP), mean arterial pressure (MAP) and CO were recorded. Results: All eleven animals tolerated the implantation of the OACC PAL. Activation of the OACC resulted in a significant increase in CO. Systolic and diastolic right ventricular pressure decreased in both groups. Lastly, counterpulsation increased the mean PAP in all animals and peak PAP reached 89 mmHg. Despite providing right heart assistance, synchronizing the counterpulsation was technically difficult, and the high peak PA pressures resulted in anastomotic bleeding in all animals and anastomotic breakdown in 4/11 animals. Conclusions: An OACC PAL perfused by the right ventricle applied in series with the pulmonary circulation reduces ventricular load and improves cardiac efficiency. These preliminary data suggest the potential of an artificial lung in unloading the strained right ventricle and acting as a bridge to transplantation. The augmented peak PA pressures, resulting in bleeding and anastomotic breakdown, and complexity in synchronizing the cardiac cycle with the pulsations of the augmented OACC, compromise this configuration. [ABSTRACT FROM AUTHOR]

Objective: Acute respiratory failure is complicated by acidosis and altered end-organ perfusion. NOVALUNG®iLA is an interventional lung assist (ILA) device for arteriovenous carbon dioxide removal (AVCO2R). The present study was conducted to evaluate the device for short-term CO2 removal performance and hemodynamic response. Methods: Six adult sheep received cannulation of the jugular vein and carotid artery. The ILA-AVCO2R circuit was placed on the sheep for 72 hours. Hemodynamics and PaCO2 were measured; CO2 removal was calculated while varying sweep gas flow rates (Qg), device blood flow rates (Qb), and PaCO2. Results: Hemodynamic variables remained normal throughout the 72 hour study. CO2 removal increased with increases in Qg or Qb. Mean CO2 removal was 119.3 ml/min for Qb 1 L/min, Qg 5 L/min, and PaCO2 40–50 mmHg. PaCO2 was directly proportional to CO2clearance (R =0.72, p <0.001). Conclusion: NOVALUNG®iLA can provide near total CO2 removal with Qb 1–2 L/min, Qg 5 L/min, and minimal flow resistance (3.88±0.82 mmHg/L/min). PaCO2 correlates with CO2 removal and is dependent on Qb and Qg. [ABSTRACT FROM AUTHOR]

Routine administration of large amounts of pain and sedative medication is common to critically ill pediatric patients undergoing extracorporeal membrane oxygenation (ECMO) for cardiopulmonary failure. It has been our experience that pediatric patients are the most difficult age group in which to achieve an ideal pain and sedative control due to the narrow margin of safety. The purpose of this study was to determine the general practice guideline used for pain and anxiolytic pharmacotherapy for pediatric patients at ECMO centers. We sent a survey questionnaire to all ECMO centers in the USA that treat pediatric respiratory failure patients. Of the 46 responding centers (including telephone follow-ups), 37 (80%) centers had an active pediatric ECMO programs for patients with severe respiratory failure. Fentanyl was the most commonly used pain medication and continuous infusion, administered directly to the patient, was preferred. Subjective effectiveness of various pharmacological agents was variable without clear consensus; however, midazolam was considered to be the most effective agent used. [ABSTRACT FROM AUTHOR]

An estimated 16 million Americans are afflicted with some degree of chronic obstructive pulmonary disease (COPD), accounting for 100,000 deaths per year. The only current treatment for chronic irreversible pulmonary failure is lung transplantation. Since the widespread success of single and double lung transplantation in the early 1990s, demand for donor lungs has steadily outgrown the supply. Unlike dialysis, which functions as a bridge to renal transplantation, or a ventricular assist device (VAD), which serves as a bridge to cardiac transplantation, no suitable bridge to lung transplantation exists. The current methods for supporting patients with lung disease, however, are not adequate or efficient enough to act as a bridge to transplantation. Although occasionally successful as a bridge to transplant, ECMO requires multiple transfusions and is complex, labor-intensive, time-limited, costly, non-ambulatory and prone to infection. Intravenacaval devices, such as the intravascular oxygenator (IVOX) and the intravenous membrane oxygenator (IMO), are surface area limited and currently provide inadequate gas exchange to function as a bridge-to-recovery or transplant. A successful artificial lung could realize a substantial clinical impact as a bridge to lung transplantation, a support device immediately post-lung transplant, and as rescue and/or supplement to mechanical ventilation during the treatment of severe respiratory failure. [ABSTRACT FROM AUTHOR]

Percutaneous cardiopulmonary support systems (PCPS) are compact, battery-powered, portable heart-lung machines that can be implemented rapidly in any area of the hospital using thin-walled cannulae inserted via the femoral vessels. PCPS provides temporary circulatory support by actively aspirating blood from the patient's venous system using a centrifugal pump and hollow fiber membrane oxygenator for gas exchange. A review of clinical reports has delineated several indications for emergent applications, with the most frequent being cardiac arrest (CA) or cardiogenic shock (CS). Survival is more likely in patients with CS (40%) compared to CA (21%). Implementation of PCPS after unwitnessed CA or cardiopulmonary resuscitation > 30 min yields a patient survival rate of <10%. The likelihood of patient survival after emergent PCPS is most often related to the patient undergoing a definitive anatomic surgical repair such as coronary artery bypass or pulmonary embolectomy. If the need for circulatory support extends beyond 6 h, conversion to conventional long-term extracorporeal membrane oxygenation or a ventricular assist device is recommended. [ABSTRACT FROM AUTHOR]

The intentional induction of elevated body temperature to treat malignant lesions has its origins in the 18th century. The mechanism of heat-induced cell death is not clear; however, heat induces a variety of cellular changes. For heat to exert a therapeutic effect, pathogens (bacteria, viruses, or neoplastic tissues) need to be susceptible within temperature ranges that do not exert deleterious effects on normal tissues. Hyperthermia has been used successfully to treat isolated neoplastic lesions of the head and neck, regional tumors such as melanoma of the limb, and is under investigation as either an adjunct to, or therapy for, locally disseminated and systemic diseases. The clinical utility of perfusion hyperthermia has evolved into three approaches - isolated organ or limb, tumorous invasion of a cavity, and systemic or metastatic spread. When wholebody hyperthermic treatment has been tried, it has been induced in the patient by submersion in hot wax or liquid, wrapping in plastic, encasement in a high-flow water perfusion suit, or by extracorporeal perfusion. Our group has developed an extracorporeal method, veno-venous perfusion-induced systemic hyperthermia, that was used first to safely heat swine homogenously to an average body temperature of 43 °C for 2 h. More recently, a Phase I clinical trial has been completed in which all patients were safely heated to 42 or 42.5 °C for 2 h and survived the 30-day study period. We have been sufficiently encouraged by these results and are continuing to develop this technology. [ABSTRACT FROM AUTHOR]

Discusses the impact of arteriovenous carbon dioxide removal on ventricular management and survival of adult patient with respiratory distress syndrome (ARDS). Pathophysiology of ARDS; Clinical management of the disease; Findings of the clinical trials conducted.

A survey of active ECMO centres regarding neonatal ECMO equipment and personnel was obtained by telephone interview in late summer 1989. Forty-seven of the centres in the USA listed in the Ann Arbor ELSO (Extracorporeal Life Support Organization) Registry at the time (>90%) were contacted and all participated. Nearly all use a roller pump, while less than 5% use a centrifugal pump. All programmes use a SciMed membrane oxygenator and 91 % a SciMed heat exchanger. Heat exchanger water sources include the Gaymar T-pump (42%), Seabrook (25%) and Cincinnati Sub-Zero (23%) units. Eighty-seven per cent use a bladder box servo-regulated to the roller pump; these are most often custom-made (69%) but 13% of programmes use a commercially available (Seabrook) bladder box. Ten per cent use a pressure-regulated roller pump rather than a conventional (displacement) bladder box to detect decreases in venous return. Nearly 80% monitor circuit line pressures between the pump and patient. Seventeen per cent use an air bubble detector on the arterial side of the circuit. Only 10% use an arterial bubble trap and 6% an arterial line filter. Seventy-five per cent do not monitor gas line pressures into the membrane lung, but one-third do use a gas line pop-off valve to prevent elevated gas phase pressures. Seventy per cent reported use of continuous in-line measurement of mixed venous oxygen saturation; no programme reported any blood chemistries being monitored in line. About 50% use an oxygen analyser for the oxygenator sweep gas and one-fifth use a blood flow meter. Fifty per cent monitor blood temperature in the circuit. Seventy-two per cent monitor activated clotting times with a Hemochron device, 21 % with a Trimed ACTester and 4% with a Hemotec ACT. The background of ECMO specialists was primarily registered nurses, but many programmes also use respiratory therapists and perfusionists. These data may provide guidance for new programmes and suggest technological improvements. [ABSTRACT FROM PUBLISHER]

To ascertain current anticoagulation management during neonatal extracorporeal membrane oxygenation (ECMO), a telephone survey was undertaken of all active ECMO (n = 81, 100% response rate) centres in the USA. Hospital policies regarding federal regulations governing laboratory tests [Clinical Laboratory Improvement Amendment (CLIA) 1988] were determined along with specific patient anticoagulation strategies and use of specific activated coagulation time (ACT) equipment. More than 90% of the respondents use the Hemochron device (International Technidyne Corp, Edison, NJ, USA) while the remaining centres use the Hemotec device (Medtronic Hemotec, Inc, Englewood, CO, USA). Quality control (QC) testing is performed by most centres, but there is no consensus regarding frequency of testing nor methods for dealing with abnormal results. Nearly one-half of the centres use beef lung-derived heparin and the other half use porcine intestinal-derived heparin. One-half of the programmes had a minimum heparin dose despite the ACT value, but the range varied significantly. Four out of five respondents reported that heparin dosages were dictated strictly by ACT results, and 63% will temporarily stop heparin administration for high ACT results, bleeding and/or surgery. Approximately one-third of the centres perform proficiency testing of the equipment in compliance with CLIA 1988. In conclusion, there appears to be no consensus regarding commitment to a QC programme among active ECMO centres. [ABSTRACT FROM PUBLISHER]

During prolonged extracorporeal perfusion, thin-walled wire-wound cannulas have become the standard for low resistance cannula access for extrathoracic cannulation. We present an unusual technique of bone wax casting to repair a leak in a cannula to continue long-term extracorporeal membrane oxygenation. [ABSTRACT FROM AUTHOR]